10-K: Alpha Teknova Reports Strong Revenue Growth, Reduced Losses in 2025

Alpha Teknova, a leading producer of critical reagents, announced a 7.4% revenue increase to $40.5 million and significantly narrowed its net loss to $17.3 million in its 2025 annual report.

Summary

• Revenue increased by 7.4% to $40.5 million in 2025, up from $37.7 million in 2024.
• Net loss significantly decreased to $17.3 million in 2025, compared to $26.7 million in 2024.
• Gross profit surged by 85.9% to $13.4 million in 2025, with gross profit percentage improving to 33.2% from 19.2% in 2024 (or 26.5% excluding non-recurring charges).
• Operating expenses decreased by 8.9% to $30.4 million in 2025, primarily due to lower research and development and general and administrative expenses.
• Lab Essentials revenue grew by 7.5% to $31.0 million, while Clinical Solutions revenue increased by 7.8% to $7.7 million in 2025.
• The company entered into a Second Amended and Restated Credit Agreement on March 3, 2025, providing a $28.245 million credit facility, and was in compliance with all financial covenants as of December 31, 2025.
• A shelf registration statement for up to $225 million in securities was declared effective on July 16, 2025, providing future financing flexibility.
• A former employee claim was settled for $0.4 million in April 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting strong revenue growth and significant improvement in profitability metrics, alongside strategic investments for future expansion. However, the company continues to incur net losses and faces ongoing risks related to market competition and reliance on key customers/suppliers.

Positives

• Net loss significantly improved from $26.7 million in 2024 to $17.3 million in 2025, indicating a positive trend towards profitability.
• Strong revenue growth of 7.4% year-over-year, reaching $40.5 million.
• Substantial improvement in gross profit percentage to 33.2% in 2025 from 19.2% in 2024 (or 26.5% adjusted for non-recurring charges).
• Operating expenses decreased by 8.9%, reflecting cost management efforts, including a reduction in workforce in early 2024.
• High customer retention rate of approximately 95% for key customers (purchasing over $10,000 annually), indicating strong customer loyalty and product integration.
• Increased manufacturing efficiency gains contributed to the gross profit improvement.
• Compliance with financial covenants under the new credit agreement as of December 31, 2025.
• Shelf registration statement for $225 million provides significant future capital raising flexibility.
• Continued growth in both Lab Essentials (7.5%) and Clinical Solutions (7.8%) product categories.
• Fast delivery times for custom Research Use Only (RUO) products (79% shipped within three weeks) and catalog RUO products (89% shipped within one week).

Negatives

• Continued operating losses, with a net loss of $17.3 million in 2025.
• Accumulated deficit increased to $135.8 million as of December 31, 2025.
• Reliance on a limited number of suppliers for certain raw materials, with two suppliers accounting for 56% of total inventory purchases in 2025.
• Customer concentration risk, with one distributor customer accounting for 21% of total revenue in 2025.
• Working capital decreased from $42.8 million in 2024 to $34.5 million in 2025.
• Short-term investments decreased significantly from $26.7 million in 2024 to $15.4 million in 2025.
• Future capital needs are uncertain, and additional financing may be required, potentially leading to dilution or unfavorable terms.
• No current plans to pay regular cash dividends, and prohibited from doing so under the Second Amended and Restated Credit Agreement without lender consent.

Risks

• Incurred operating losses in the past and may incur losses in the future, with no assurance of achieving or maintaining profitability.
• Operating results may fluctuate significantly and are difficult to predict, potentially falling below expectations or any guidance provided.
• Significant capital investment in manufacturing facilities may not yield anticipated benefits or timelines, potentially disrupting operations.
• Natural disasters (including earthquakes, fire, and drought), geopolitical unrest, war, terrorism, public health issues, or other catastrophic events could disrupt supply, production, delivery, or demand.
• Inability to maintain current customer relationships, sustain recurring revenue, or enter new customer relationships could adversely affect future operating results.
• Intense competition from larger life science, pharmaceutical, and biotechnology companies, some of whom are also customers, potentially leading to product obsolescence or pricing pressure.
• Future capital needs are uncertain, and additional financing may not be secured on favorable terms, if at all, potentially leading to dilution.
• Future acquisitions may expose the company to risks and may not achieve anticipated benefits.
• Estimates of market sizes and opportunities may be inaccurate, and business growth may not match forecasted market growth.
• Extensive and evolving laws and regulations, including data privacy and information security, could increase costs and time for compliance.
• Reliance on assumptions, estimates, and data for key metrics, with potential inaccuracies harming reputation and business.
• Inability to protect intellectual property (primarily trade secrets) could materially adversely affect the value of technology and products.
• Terms of the Second Amended and Restated Credit Agreement restrict current and future operations, and failure to comply could lead to acceleration of debt or foreclosure.
• Telegraph Hill Partners Management Company LLC controls the company (70.4% voting power), and its interests may conflict with other stockholders.
• Material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting.
• Requirements of being a public company, especially after ceasing to be an emerging growth company or smaller reporting company, may strain resources and distract management.
• Provisions in corporate governance documents could make acquiring the company more difficult and prevent stockholder attempts to replace directors or management.
• Product liability lawsuits could cause substantial liabilities, limit sales, and damage reputation.
• Dependence on a stable and adequate supply of quality raw materials, with price increases or interruptions adversely impacting the business.
• Inability to manufacture or ship products to meet demand could harm operating results.
• Reliance on third-party package delivery services, with disruptions, damages, or price increases adversely affecting the business.
• Inability to hire and retain skilled personnel could hinder product development and marketing.
• Failure to maintain corporate culture as the company grows could harm the business.
• Failure to successfully identify and implement additional distribution arrangements and marketing alliances on favorable terms may impair product distribution and marketing.
• Market acceptance of bacterial cell culture media, specialized chromatography solutions, and molecular biology reagents manufactured to GMP quality standards is crucial for commercial success.
• Strategic and operational decisions to prioritize certain markets and product offerings may prove suboptimal.
• Unforeseen adverse events, negative clinical outcomes, or increased regulatory scrutiny of novel treatments (cell/gene therapy, mRNA vaccines) could damage public perception and harm customer business.
• Products could become subject to FDA or other regulatory agency regulation in the future, increasing costs and delaying commercialization.
• Fluctuations in effective tax rate may adversely affect results of operations and cash flows.
• Estimates or judgments relating to critical accounting policies may prove incorrect, affecting operating results.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Employees, consultants, distributors, and commercial partners may engage in misconduct or improper activities.
• Operating results and stock price may be volatile, and market volatility could lead to litigation.
• If securities or industry analysts publish unfavorable research, change recommendations, or cease coverage, stock price and trading volume could decline.
• Potential for various claims, litigation, or investigations to have a material adverse effect on the business.

Future Outlook

The company anticipates continued growth in the life sciences R&D spending, particularly in emerging therapeutic and diagnostic modalities like cell and gene therapies, mRNA, vaccines, liquid biopsy, and genomics. It plans to increase integration of its products into customer workflows, provide superior customer service through operational excellence and automation, and pursue selective geographic expansion and strategic partnerships, especially in Europe. The company expects operating expenses to increase modestly in future periods but at a slower rate, driven by personnel, infrastructure investments, brand awareness, and sales efforts.

Management Comments

• Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable.
• We believe the bespoke nature of our portfolio makes us a critical, trusted supplier to our customers.
• We believe our prospects for growth will also benefit from developments in other fields, including mRNA, vaccines, liquid biopsy, and genomics.
• Our goal is to provide our customers the products necessary to accelerate their therapeutic and diagnostic development efforts, from basic research to commercialization of therapies that improve human health.
• We believe these investments position us for future growth by allowing us to continue to exceed our customers expectations in quality and turnaround time and enabling us to maintain lasting relationships with our customers as they advance their products through key phases of product development.
• We believe the local supply base in Europe is not able to produce customer-specified formulations with the diversity and scale necessary to satisfy the corresponding demand, with the short turnaround times customers expect.
• We believe we have access to adequate supplies of water for our manufacturing operations and currently do not anticipate that future drought conditions will have a material impact on our operating results.

Industry Context

StockSavvy.ai notes that Alpha Teknova operates within a highly competitive and rapidly evolving life sciences market, benefiting from increasing R&D funding and the expansion of high-growth areas such as cell and gene therapy, mRNA vaccines, and molecular diagnostics. The company's focus on custom, made-to-order, and GMP-grade reagents with short turnaround times positions it well to capitalize on the industry's demand for adaptable, end-to-end providers, especially as therapies move through clinical trials and require increasingly stringent regulatory compliance. The market's shift towards single-use bioreactors also favors Teknova's capabilities for smaller build sizes. However, the industry faces economic uncertainties, including inflation and interest rate changes, which can impact customer R&D spending, as seen in the contraction of funding for small biotechnology companies in 2022-2024.

Comparison to Industry Standards

• The company's 95% customer retention rate for key customers (purchasing over $10,000 annually) is a strong indicator of customer loyalty and product integration, potentially outperforming general industry churn rates for specialized suppliers.
• The ability to move new custom products into production in weeks, compared to months from alternative suppliers, provides a significant competitive advantage in the life sciences market, where speed to market is critical for therapeutic and diagnostic development.
• The company's ISO 13485:2016 certification for Clinical Solutions products aligns with global benchmarks for quality systems in the medical device industry, enabling it to serve customers with stringent regulatory requirements for diagnostic and therapeutic applications.
• The predicted increase in average customer spend for cell and gene therapies (1.4x in Phase 2, 3.2x in Phase 3, 29.8x in commercial production compared to Phase 1) highlights a significant growth opportunity that Teknova is positioned to capture, assuming its customers successfully advance their products.
• The global molecular diagnostics market is projected to grow from $31.9 billion in 2025 to $81.6 billion by 2032, and the global genomics market from $21.8 billion in 2025 to $72.5 billion by 2033. Teknova's participation in these markets positions it to benefit from this substantial projected growth, indicating alignment with high-growth industry segments.

Corporate Governance

Legal Proceedings

• A former Teknova employee filed a claim in August 2023 alleging various causes of action under California's labor, wage, and hour laws.
• The company agreed to settle the claims for $0.4 million on June 6, 2024.
• The settlement received final court approval in April 2025, and the company paid the $0.4 million amount.
• No other material legal proceedings are currently ongoing.

Related Party Transactions

• Telegraph Hill Partners Management Company LLC (THP), through its affiliates, controls approximately 70.4% of the voting power of the company's outstanding common stock.
• THP and its affiliates, along with the company's President and CEO (Stephen Gunstream) and CFO (Matthew Lowell), participated in the July 2024 Offering, collectively purchasing 12,217,740 shares.
• The company's amended and restated certificate of incorporation allows THP and its affiliates to engage in business activities that may conflict with the company's interests and does not obligate them to offer corporate opportunities to the company.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance and strategic growth initiatives, but also dilution risk from future equity raises and influence of controlling shareholder (THP).
• Employees: Reduction in force in early 2024 impacted 35 positions. Ongoing focus on attracting, retaining, incentivizing, and motivating skilled personnel. Stock-based compensation plans are in place.
• Customers: Continued focus on high-quality, custom, and GMP-grade products with short turnaround times aims to enhance customer satisfaction and retention.
• Suppliers: Dependence on a limited number of key suppliers poses a risk if supply is disrupted or prices increase.
• Creditors: The company is in compliance with financial covenants under its Second Amended and Restated Credit Agreement, indicating good standing with its lender.

Next Steps

• Increase integration of products into customer workflows, aiming to convert more catalog customers to custom and GMP-grade products.
• Continue investing in automation, facilities, and operating infrastructure to increase manufacturing capacity, improve efficiency, and reduce turnaround times.
• Pursue selective geographic expansion into markets outside the U.S., particularly in Europe, through distribution partners, localized manufacturing, or acquisitions.
• Explore partnerships, collaborations, or acquisitions in existing and adjacent market segments.
• Continue to attract, hire, and retain qualified personnel.
• Build brand awareness and market presence through targeted marketing initiatives and expanded sales efforts.
• Monitor and comply with evolving data privacy and information security laws and regulations.
• Address potential future challenges related to raw material supply, competition, and regulatory changes in the life sciences industry.

Key Dates

Recommendation

Alpha Teknova demonstrated significant financial improvement in 2025 with strong revenue growth and a narrowed net loss, indicating positive operational momentum and effective cost management. The strategic focus on high-growth markets like cell and gene therapy, coupled with investments in manufacturing and a high customer retention rate, suggests a solid long-term business model. However, the company remains unprofitable, has a substantial accumulated deficit, and faces ongoing risks from market competition, supplier/customer concentration, and the influence of its controlling shareholder. While the positive trends are encouraging, the inherent risks and the need for future capital raises warrant a 'hold' recommendation, advising investors to monitor continued progress towards sustained profitability and effective risk mitigation before considering further investment.

Keywords

reagents, life sciences, biotechnology, pharmaceutical, molecular diagnostics, cell therapy, gene therapy, mRNA vaccines, GMP, Lab Essentials, Clinical Solutions, SEC filing, 10-K, financial performance, corporate governance, risk management, manufacturing, supply chain, intellectual property, Nasdaq, TKNO